Phathom Pharmaceuticals More Than Doubles VOQUEZNA Revenues and Eyes Profitability in 2026

Revenue Growth Surges as VOQUEZNA Prescriptions Top 1.35 Million

Phathom Pharmaceuticals (NASDAQ: PHAT) marked notable commercial and financial progress in the first quarter of 2026, highlighted by a 104% year-over-year revenue increase for its lead gastrointestinal therapy VOQUEZNA. The company reported $58.3 million in net revenues, with approximately 1.35 million total VOQUEZNA prescriptions filled to date and 268,000 filled in the quarter—a 115% jump from the prior year.

These gains are not just impressive in volume, but in quality: covered prescriptions for Q1 2026 grew 91% over the same period last year, now accounting for about 63% of total prescriptions. As the new sales team structure takes hold, data from April show all-time weekly highs for prescription coverage, signaling renewed demand momentum. The company remains confident in its goal of reaching $1 billion in annualized revenues for VOQUEZNA over time.

Disciplined Spending and Cost Controls Accelerate Path to Profitability

Operational discipline was a clear theme this quarter. Operating expenses dropped sharply by 40% year-over-year to $61.8 million, while non-GAAP operating expenses—excluding non-cash stock-based compensation—declined to $56.2 million. Net cash usage for the period was limited to $15 million, a significant improvement from the prior year, even as Phathom continued investing in its commercial team and clinical pipeline.

The company expects this trajectory to continue, maintaining its FY 2026 guidance and aiming for operating profitability by Q3 2026 and full-year 2026. Cash and cash equivalents stood at $180.9 million as of March 31, 2026, strengthened by a recent equity raise and targeted debt repayment. Based on current plans, management projects that available cash and future cash flows should cover all obligations without requiring further fundraising.

Insurance Coverage Expands, Strengthening Demand Outlook

The company's emphasis on GI-focused sales and access appears to be paying off. About 30% of 'new-to-brand' prescriptions among the top 3,000 GI prescribers now go to VOQUEZNA, making considerable inroads against traditional PPIs. Management acknowledges some seasonal insurance pressure in Q1 but has already documented a rebound in late March and early April. On top of commercial traction, the gross margin remains robust at 80%, and gross-to-net discounts align with industry expectations at 55%–59%.

Clinical Pipeline and Capital Position Provide Forward Visibility

Phathom’s EoE clinical trial, the Phase 2 pHalcon-EoE-201 study, is enrolling patients ahead of schedule, with topline data anticipated in late Q4 2026 or early Q1 2027. The company maintains a strong balance sheet, reporting $180.9 million in cash and cash equivalents and a substantial reduction in liabilities from the prior quarter. This financial flexibility, coupled with positive operational trends, underpins the company’s guidance for $320–$345 million in net revenues for the full year.

Takeaway: Phathom Poised for Profitability as VOQUEZNA Growth Accelerates

In summary, Phathom Pharmaceuticals delivered on multiple fronts this quarter: rapid revenue gains, prudent expense management, and a strengthening prescription and payer landscape. Operating profitability is now within reach for the back half of 2026, with cash flow positivity projected for 2027. For investors and industry watchers, Phathom’s execution and guidance suggest the company is positioned to unlock further value as it continues its expansion in the GI market. Investors may want to keep an eye on upcoming clinical milestones and prescription data, as both will be important indicators of Phathom’s progress toward sustained profitability.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI